-- Ace Therapeutics, a trusted provider of high-quality preclinical research and development services, has officially released a comprehensive suite of behavioral testing solutions including sensory testing in rodent stroke model, designed to support precise evaluation of somatosensory function and pain‑related behavioral changes in preclinical stroke research. The behavioral assessment of sensory service covers mechanical, thermal, and cold nociceptive assessments, with standardized protocols to deliver reproducible, objective data for drug efficacy validation and post‑stroke brain repair studies.
Sensory impairment is a common and clinically relevant consequence of stroke, often manifesting as reduced tactile, pain, temperature, or proprioceptive perception, as well as altered object recognition. Changes in pain sensitivity and thresholds are widely recognized as key functional outcome measures in preclinical stroke research. To address this critical need, Ace Therapeutics offers a full panel of behavioral assays to quantify mechanical allodynia, thermal hyperalgesia, and cold hypersensitivity in rodent stroke models.
A core component of the offering is the mechanical allodynia Von Frey test service, which uses calibrated Von Frey filaments to measure paw withdrawal thresholds or response rates in rats and mice, delivering reliable indicators of mechanical hypersensitivity after stroke. Ace Therapeutics also employs dynamic plantar aesthesiometry as a complementary automated approach, enabling rapid, consistent measurement of withdrawal thresholds. Both methods are performed at standardized time points: 1 day before surgery and on days 1, 3, 5, 7, 10, 14, and 21 post‑stroke, supporting longitudinal functional profiling.
Beyond mechanical allodynia testing, Ace Therapeutics provides thermal hyperalgesia assessment using radiant heat stimulation with automated termination upon paw withdrawal, minimizing subjective bias. For cold nociceptive evaluation, Ace Therapeutics offers 3 validated approaches: the acetone test, cold plate test, and cold plantar assay, each with defined scoring systems, latency measurements, and normal reference ranges for rats and mice. All tests follow blinded observer protocols and include 30‑minute acclimatization to reduce experimental variability, ensuring data integrity across studies.
"Our specialized sensory testing platform in rodent stroke models fills a key gap in preclinical neuroprotection research," commented a senior scientist at Ace Therapeutics. "By combining rigorous rodent stroke model sensory testing with dedicated services such as the mechanical allodynia Von Frey test service, we enable researchers to accurately characterize somatosensory dysfunction and objectively evaluate therapeutic interventions aimed at restoring brain function after stroke.”
For more information about Ace Therapeutics' sensory assessment services or other drug efficacy testing for stroke, please visit its official website or contact its expert team.
About Ace Therapeutics
Ace Therapeutics specializes in preclinical evaluation and drug efficacy testing for stroke. With advanced equipment and a team of experienced scientists, Ace Therapeutics provides standardized, reproducible behavioral assessment services to accelerate the discovery and development of novel therapies for neurological diseases.
Contact Info:
Name: Daisy Mostert
Email: Send Email
Organization: Ace Therapeutics
Website: https://www.acetherapeutics.com/stroke/
Release ID: 89188533
Google
RSS